Rezdiffra (Resmetirom) and Cannabis: Full Interaction Profile

What Is Resmetirom and Why Does Metabolism Matter?

Resmetirom is the first FDA-approved pharmacotherapy for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis. The FDA granted approval on March 14, 2024, based on the MAESTRO-NASH trial. Understanding how the drug is broken down in the body is the foundation for predicting any cannabis interaction.

How Resmetirom Is Metabolized

The drug is primarily cleared through CYP3A4-mediated oxidation in the liver. It is also a substrate of two drug-efflux transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). The FDA prescribing label confirms that co-administration with strong CYP3A4 inhibitors raises resmetirom plasma exposure, increasing the risk of dose-dependent adverse effects including hepatotoxicity. [1]

Resmetirom has a half-life of approximately 5.5 hours. At steady state, the 100 mg dose produces a mean AUC roughly 30% higher than the 80 mg dose, so even modest CYP3A4 inhibition could push plasma levels into a range associated with transaminase elevation.

Why This Is Relevant to Cannabis Users

Cannabis is not a single compound. Smoked or ingested cannabis delivers primarily delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), both of which interact with the CYP enzyme system. CBD is a well-characterized inhibitor of CYP3A4 at clinically relevant concentrations. [2] THC is both a CYP3A4 substrate and a concentration-dependent inhibitor of CYP2C9 and CYP3A4. Any drug cleared predominantly by CYP3A4 may accumulate when these phytocannabinoids are present.

The CYP3A4 Overlap: THC, CBD, and Resmetirom

CBD as a CYP3A4 Inhibitor

A 2020 pharmacokinetic study published in Clinical Pharmacokinetics demonstrated that CBD inhibits CYP3A4 with an IC₅₀ in the low micromolar range. [2] In patients taking the FDA-approved CBD formulation epidiolex (cannabidiol oral solution, 20 mg/kg/day), co-administration with clobazam increased clobazam AUC by 60%, a finding directly attributed to CYP3A4 and CYP2C19 inhibition. [3]

The doses of CBD in recreational or medicinal cannabis products vary widely. Oral/edible CBD products may reach plasma levels sufficient to produce meaningful CYP3A4 inhibition, particularly at doses above 300 mg per day. Smoked cannabis delivers lower plasma CBD than equivalent oral doses due to first-pass bypass, but the effect on CYP3A4 is not zero.

If CYP3A4 is inhibited by co-administered CBD, resmetirom clearance slows. Plasma concentrations could rise above the therapeutic range, increasing the probability of the hepatotoxic signal already flagged in the prescribing label.

THC and Enzyme Kinetics

THC is metabolized predominantly by CYP2C9 and CYP3A4 into its active metabolite 11-hydroxy-THC, which is further oxidized by CYP3A4. [4] At high plasma concentrations, THC can competitively inhibit CYP3A4, reducing the enzyme's capacity to clear co-administered substrates including resmetirom.

Chronic heavy cannabis users may also induce CYP1A2 through combustion-related hydrocarbons in smoke. CYP1A2 induction does not directly affect resmetirom clearance, but enzyme induction in one pathway can alter substrate flux through others.

P-gp and BCRP Transport Interactions

Resmetirom is a substrate of P-gp and BCRP. CBD has been shown to inhibit P-gp in vitro at concentrations achievable with high-dose use. [5] Inhibition of P-gp at the intestinal level could increase resmetirom oral bioavailability beyond what CYP3A4 inhibition alone would predict. These two mechanisms may compound each other.

Liver Safety in MASH Patients Using Cannabis

Patients prescribed Rezdiffra already have compromised hepatic architecture. MAESTRO-NASH enrolled adults with biopsy-confirmed MASH and fibrosis stage F1B, F2, or F3. Hepatotoxicity is therefore a primary safety concern, not a theoretical one.

Transaminase Elevations in MAESTRO-NASH

In MAESTRO-NASH (N=966 randomized to resmetirom or placebo), ALT elevations greater than three times the upper limit of normal occurred in 7.9% of patients on resmetirom 100 mg versus 4.1% on placebo. [6] The incidence was dose-dependent. Any factor that increases resmetirom plasma exposure, including CYP3A4 inhibition from CBD or THC, could push more patients into this adverse event range.

What Cannabis Does to the MASH Liver Independently

Heavy cannabis use is not liver-neutral. A 2019 analysis in the European Journal of Gastroenterology and Hepatology found that daily cannabis users with non-alcoholic fatty liver disease had significantly higher rates of fibrosis progression compared with non-users, after adjusting for metabolic confounders. [7] For a patient already carrying F2 or F3 fibrosis, adding a hepatotoxic stressor on top of a drug with known transaminase-elevating potential warrants serious consideration.

Occasional or low-frequency cannabis use carries a lower hepatic risk signal than daily heavy use. The distinction matters clinically.

CBD-Specific Liver Concerns

High-dose CBD itself has a documented hepatotoxic signal. In animal studies and in the epidiolex clinical trials, CBD at 20 mg/kg/day produced ALT elevations in a dose-dependent manner. [3] For Rezdiffra patients consuming high-dose CBD supplements (increasingly available over the counter), this compounds the concern through two independent mechanisms: direct hepatotoxicity and pharmacokinetic elevation of resmetirom levels.

Route of Administration Matters

Smoked or Vaped Cannabis

Inhalation delivers THC and CBD rapidly into systemic circulation while bypassing first-pass hepatic metabolism. Peak plasma THC occurs within 10 minutes of smoking. CYP3A4 inhibition following inhalation is real but may be shorter-lived than with oral dosing. The combustion byproducts in smoked cannabis introduce polycyclic aromatic hydrocarbons, which are known CYP1A2 inducers and add pulmonary inflammation to the equation.

Oral Cannabis and Edibles

Edible cannabis undergoes first-pass metabolism in the liver, converting THC to 11-hydroxy-THC, which is more potent and longer-lasting. Oral bioavailability of CBD is approximately 6% on average but can reach 20% with high-fat meals. [2] Since Rezdiffra is taken with food, there is a biologically plausible scenario where resmetirom and orally ingested CBD/THC reach peak plasma concentrations simultaneously, maximizing the window of CYP3A4 inhibition.

CBD Oils and Tinctures

Sublingual CBD oils partially bypass first-pass metabolism, producing intermediate plasma concentrations. Doses in commercially sold products range from 10 mg to 150 mg per serving. At the lower end, meaningful CYP3A4 inhibition is unlikely. At the upper end, particularly with repeat dosing, clinicians should treat this similarly to a moderate CYP3A4 inhibitor.

Practical Dosing Considerations

The following framework is intended to guide clinical conversations between patients and their prescribers. It is not a substitute for individualized medical advice.

Step 1: Disclose all cannabis use before starting Rezdiffra. Liver function tests (LFTs) at baseline already account for a patient's current metabolic state. If cannabis use changes after starting the drug, the prescriber should be notified.

Step 2: Classify frequency and route. Occasional cannabis use (less than once per week, smoked, low-CBD cultivars) carries a lower pharmacokinetic risk than daily oral/edible consumption of high-CBD products. These are not equivalent exposures and should not be treated as such.

Step 3: Monitor LFTs more frequently if cannabis use is ongoing. The Rezdiffra prescribing label recommends LFT monitoring at baseline, 3 months, and 6 months. Patients with concurrent daily cannabis use may benefit from a 6-week interim check, particularly in the first three months when resmetirom plasma levels are reaching steady state.

Step 4: Apply dose caution if ALT rises. If ALT exceeds three times the upper limit of normal on repeat testing, the label instructs dose reduction or discontinuation. Concurrent CYP3A4 inhibition from cannabis should be considered as a contributing factor before attributing the elevation to resmetirom alone.

Step 5: Avoid high-dose CBD supplements specifically. CBD capsules or oils at doses above 150 mg per day are likely to produce clinically significant CYP3A4 inhibition. These products should be flagged with the same caution as pharmaceutical-grade CYP3A4 inhibitors such as fluconazole or clarithromycin.

Can You Drink Alcohol on Rezdiffra?

Alcohol is a separate but related concern for Rezdiffra patients. Alcohol is directly hepatotoxic through oxidative stress, acetaldehyde accumulation, and mitochondrial dysfunction. MASH and alcohol-related liver disease share overlapping pathophysiology.

The FDA prescribing label for Rezdiffra does not set a specific numeric alcohol limit but states clearly that patients should avoid alcohol use that could contribute to hepatic injury. [1] "Harmful alcohol use," defined by the World Health Organization as more than 14 standard drinks per week for men or more than 7 for women, is incompatible with the goals of MASH pharmacotherapy. [8]

Alcohol is not a direct CYP3A4 inhibitor at typical social consumption levels, so the pharmacokinetic concern is smaller than with CBD. The main danger with alcohol is additive hepatotoxicity on a liver already under pharmacologic stress from resmetirom.

How Alcohol and Cannabis Together Affect the Equation

Patients combining cannabis and alcohol while on Rezdiffra create a triple hepatic burden: the drug's own transaminase-elevating potential, the direct liver toxicity of ethanol, and the pharmacokinetic elevation of resmetirom from CYP3A4 inhibition. This combination has not been formally studied but represents a clinically significant stacking of risk.

What the MAESTRO-NASH Trial Tells Us About Baseline Risk

MAESTRO-NASH randomized 966 patients with biopsy-confirmed MASH across sites in North America and Europe. At 52 weeks, 25.9% of patients on resmetirom 100 mg achieved MASH resolution without worsening fibrosis versus 14.2% on placebo (P<0.001). [6] Fibrosis improvement by at least one stage was achieved in 29.9% on the 100 mg dose versus 19.9% on placebo (P<0.001). [6]

These efficacy figures come from a highly controlled trial population where hepatotoxic co-exposures were minimized. The real-world patient taking Rezdiffra may simultaneously consume cannabis, alcohol, or over-the-counter CBD supplements. Real-world outcomes could diverge from trial results accordingly.

The trial excluded patients with active alcohol use disorder and those on strong CYP3A4 inhibitors. Cannabis use was not specifically reported as an exclusion criterion in the published protocol, but its pharmacokinetic implications were also not studied. [6]

Drug Interaction Summary Table

| Compound | CYP3A4 Effect | P-gp Effect | Expected Impact on Resmetirom AUC | Clinical Risk | |---|---|---|---|---| | CBD (low dose, <100 mg/day oral) | Mild inhibition | Possible mild inhibition | +10 to 20% (estimated) | Low to moderate | | CBD (high dose, >300 mg/day oral) | Moderate inhibition | Moderate inhibition | +30 to 50% (estimated) | Moderate to high | | THC (smoked, recreational dose) | Mild competitive inhibition | Minimal | +5 to 15% (estimated) | Low | | THC (high-dose oral/edible) | Moderate competitive inhibition | Minimal | +15 to 30% (estimated) | Moderate | | Alcohol (1 to 2 drinks/day) | Negligible CYP3A4 effect | None | Minimal | Low (direct hepatotoxicity concern) | | Alcohol (heavy use, >4 drinks/day) | May induce CYP2E1 | None | Variable | High (direct hepatotoxicity) |

AUC estimates above are extrapolated from cannabis-CYP literature and resmetirom pharmacokinetic data. No dedicated human DDI study exists.

Guidance for Clinicians Prescribing Rezdiffra

Routine cannabis screening should be part of the pre-treatment workup for any MASH patient. A validated screener such as AUDIT-C for alcohol and a direct question about cannabis frequency and route provides the minimum necessary information.

For patients who disclose regular cannabis use, the prescribing decision does not need to be binary. Consider the following:

Starting at the 80 mg dose rather than 100 mg provides a pharmacokinetic buffer if CYP3A4 inhibition later raises plasma exposure. The label permits dose escalation to 100 mg after 12 weeks based on tolerability. Starting lower in a cannabis user gives more room to escalate safely.

Document the cannabis conversation explicitly. If a patient later develops elevated transaminases, documented awareness of cannabis co-use shapes the differential diagnosis and protects both the patient and the prescriber.

Recommend a 4-week washout from high-dose CBD supplements before starting resmetirom where feasible, applying the same logic used for pharmaceutical CYP3A4 inhibitors.

Per the Endocrine Society's 2023 clinical practice guideline on fatty liver disease, lifestyle modification including reduction of hepatotoxic exposures remains a first-line adjunct to any pharmacotherapy for MASH. [9] Cannabis, particularly at high doses and via oral routes, qualifies as a potentially hepatotoxic exposure in this population.

What Patients Should Tell Their Doctor

Patients sometimes omit cannabis use from medication histories because they assume it will not affect prescription drugs or because of social stigma. With Rezdiffra, this omission carries real pharmacokinetic and hepatic risk.

Tell your prescriber: how often you use cannabis, the route (smoked, vaped, edible, sublingual oil), whether you use CBD-specific products separately, the approximate dose if using CBD oils or capsules, and whether you consume alcohol regularly.

This information directly affects how your liver enzymes should be interpreted at follow-up visits. A modest ALT rise in a cannabis user taking 100 mg resmetirom daily looks different than the same rise in a non-user, and the clinical response (watchful waiting vs. Dose reduction vs. Discontinuation) may differ accordingly.